Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) ( Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) ) publish the annual report of 2021 on the evening of March 17. In 2021, the company achieved an operating revenue of 5.75 billion yuan, an increase of 144.25% over the same period of last year; The net profit attributable to shareholders of listed companies was 2.021 billion yuan, an increase of 198.59% over the same period last year; The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 1.946 billion yuan, an increase of 215.32% over the same period of last year. The company plans to give 2 bonus shares for every 10 shares to all shareholders and distribute a cash dividend of 2 yuan (including tax). At the same time, it is proposed to increase 2.5 shares for every 10 shares to all shareholders.
Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) during the investigation, it was introduced that in 2021, the company’s bivalent HPV vaccine continued to maintain prosperous production and sales, with rapid growth in revenue and profit. The vaccine sales exceeded 10 million and the revenue exceeded 3 billion yuan. As the covid-19 pneumonia epidemic has not been effectively controlled, the demand for overseas testing has increased significantly, and the company’s covid-19 raw material sales and overseas testing reagent export revenue have increased rapidly.
It is worth noting that the cash flow from operating activities in Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) 2021 reached 1.682 billion yuan, a year-on-year increase of 259.23%. In this regard, the company said that the increase was mainly due to the collection brought by the sales of bivalent cervical cancer vaccine and the collection brought by the sales of overseas covid-19 pneumonia detection kit in this period, resulting in a sharp increase in the cash received from the sales of goods.
The financial report shows that in the field of vaccine, bivalent HPV vaccine passed the WHO pre certification during the reporting period; The phase III clinical trial of nine valent HPV vaccine is progressing smoothly. The main clinical trial has completed the enrollment and vaccination, and the visit is ongoing. The head-to-head clinical trial with jiadaxiu 9 has completed the on-site work, and the young age bridging clinical trial has also been started and the enrollment work has been completed; The traditional lyophilized live attenuated varicella vaccine obtained the phase III clinical trial report; The new freeze-dried live attenuated varicella vaccine (vzv-7d) has completed phase IIa clinical trial and is carrying out phase IIB clinical trial; Nasal spray covid-19 vaccine entered the phase III clinical trial stage of international multi center, and successfully promoted the phase III clinical trial; The 20 valent pneumonia vaccine was approved by clinical implication.
Regarding the planned production capacity and terminal sales of bivalent HPV vaccine in 2022, which is concerned by the market, Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) in the research summary disclosed on March 16, said that from the perspective of the market demand for cervical cancer vaccine in 2021, the market demand will remain strong in the next few years. Based on the principle of giving priority to supporting government projects, while paying attention to market demand and competitors, the company will carry out reasonable planning and market promotion to maximize market supply.
